Pacira BioSciences, Inc. (PCRX) Q3 2025 10-Q Quarterly Report
Pacira BioSciences, Inc. (PCRX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Pacira BioSciences, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: Settlement with eVenus ANDA Filers allows limited generic sales starting early 2030, volume capped rising from high single-digit to high thirties % by late 2030s
- • Updated risk: Patent infringement litigation expanded with new suits filed in Dec 2024, and new declaratory judgment action by eVenus ANDA Filers in 2025
- • Regulatory risk: Multiple Paragraph IV certifications received in Oct 2025 from Chinese generic firms challenging EXPAREL patents, triggering 45-day lawsuit window
- • Operational risk: Competitors with alternative delivery systems for bupivacaine threaten commercial opportunity by avoiding pMVL patent scope
- • Financial risk: $7.0 million settlement payment to eVenus ANDA Filers recognized for litigation resolution and future royalty/license agreements
Get deeper insights on Pacira BioSciences, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.